[Evaluation of remicade efficiency for the treatment of rheumatoid arthritis].
The treatment of patients with severe rheumatoid arthritis (RA), who have resistance to basic anti-inflammatory medications (BAIM) has not been always effective. Moreover, a prolonged use of BAIM can cause side effects. Nowadays, REMICADE biological preparation has been used in practical activity by rheumatologists as an inhibitor TNF-alpha. The use of Remicade during 52 weeks gives positive results and improves existence quality of patients with RA.
Sultanova
T Zh
TZh
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy*; D002097:C-Reactive Protein / Q000032:analysis; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D016896:Treatment Outcome; D055815:Young Adult
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D002097:C-Reactive Protein; D000069285:Infliximab